WASHINGTON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced significant additions to the body of high-quality evidence presented and published during the Transcatheter Cardiovascular Therapeutics (TCT) conference, addressing the critical needs of patients with structural heart disease..

华盛顿--（商业新闻短讯）--爱德华兹生命科学公司（纽约证券交易所：EW）今天宣布，在经导管心血管治疗（TCT）会议期间提出并发表的高质量证据的主体有了重大补充，以满足结构性心脏病患者的关键需求。。

“The data at TCT on Edwards’ innovations underscore our commitment to scientific leadership and our focus to bring impactful and life-saving structural heart therapies to patients and physicians,” said Bernard Zovighian, Edwards’ CEO. “This new clinical evidence also advances Edwards’ opportunities within both TAVR and TMTT to treat more patients with our advanced technologies and support long-term, sustainable growth across the company in the years ahead.”.

爱德华兹首席执行官伯纳德·佐维吉安（BernardZovighian）表示：“TCT关于爱德华兹创新的数据突显了我们对科学领导力的承诺，以及我们对为患者和医生带来有影响力和挽救生命的结构性心脏疗法的关注。”。“这一新的临床证据也促进了爱德华兹在TAVR和TMTT中利用我们的先进技术治疗更多患者的机会，并在未来几年支持公司的长期可持续发展。”。

The data, including results from the groundbreaking EARLY TAVR and TRISCEND II trials, highlighted outcomes from studies that focused on previously understudied patient groups. The findings emphasized that timely treatment of structural heart disease not only enhances clinical outcomes and quality of life for patients, but also reduces long-term healthcare costs..

这些数据，包括开创性的早期TAVR和TRISCEND II试验的结果，突出了以前研究不足的患者群体的研究结果。。。

Transcatheter Aortic Valve Replacement (TAVR)

经导管主动脉瓣置换术（TAVR）

New data provided compelling evidence about TAVR, particularly for patients without symptoms but suffering from severe aortic stenosis, including:

新数据提供了关于TAVR的令人信服的证据，特别是对于没有症状但患有严重主动脉瓣狭窄的患者，包括：

A meta-analysis highlighting the importance of early intervention in asymptomatic severe aortic stenosis patients and reinforcing the results from the EARLY TAVR trial.

一项荟萃分析强调了无症状严重主动脉瓣狭窄患者早期干预的重要性，并加强了早期TAVR试验的结果。

A pooled analysis of RHEIA + PARTNER 3 data highlighting the efficacy and safety of Edwards TAVR in women.

RHEIA+PARTNER 3数据的汇总分析突出了Edwards TAVR在女性中的有效性和安全性。

Insights into delays in care for aortic valve replacement (AVR), finding pre-procedural requirements contribute to TAVR patients waiting significantly longer than SAVR patients to access treatment.

深入了解主动脉瓣置换术（AVR）护理的延迟，发现术前要求有助于TAVR患者比SAVR患者等待治疗的时间明显更长。

An assessment of the value of timely treatment of aortic stenosis, finding that intervening at earlier stages of cardiac damage helps save costs and healthcare resources.

评估及时治疗主动脉瓣狭窄的价值，发现在心脏损伤的早期阶段进行干预有助于节省成本和医疗资源。

Transcatheter Mitral and Tricuspid Therapies (TMTT)

经导管二尖瓣和三尖瓣治疗（TMTT）

Additionally, new evidence was presented on Edwards’ portfolio of transcatheter mitral and tricuspid repair and replacement therapies, reinforcing the strength of the company’s innovations beyond TAVR, including:

此外，Edwards的经导管二尖瓣和三尖瓣修复和替代疗法组合提供了新的证据，增强了公司在TAVR之外的创新实力，包括：

The two-year outcomes from the pivotal CLASP IID trial, showcasing sustained benefits of PASCAL in treating degenerative mitral regurgitation in a broad patient population.

关键的CLASP IID试验的两年结果显示了PASCAL在治疗广泛患者人群退行性二尖瓣关闭不全方面的持续益处。

An analysis of the healthcare resource utilization and costs associated with tricuspid regurgitation, highlighting the economic impact of timely intervention.

分析与三尖瓣关闭不全相关的医疗资源利用和成本，强调及时干预的经济影响。

One-year results from the TWIST global feasibility study, demonstrating promising outcomes for Innovalve in transcatheter mitral valve replacement, which was recently acquired by Edwards.

TWIST全球可行性研究的一年结果表明，Innovalve在经导管二尖瓣置换术中取得了有希望的结果，最近被Edwards收购。

Data from the PASTE registry, encompassing more than 1,000 European patients treated with PASCAL in the tricuspid position, underscoring its safety and effectiveness.

来自PAST登记处的数据，包括1000多名在三尖瓣位置接受PASCAL治疗的欧洲患者，强调了其安全性和有效性。

About Edwards Lifesciences

关于爱德华兹生命科学

Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most.

爱德华兹生命科学公司是全球领先的结构性心脏创新公司，致力于改善患者生活。。

Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube..

请访问www.edwards.com了解更多信息，并在LinkedIn、Facebook、Instagram和YouTube上关注我们。。

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend the forward-looking statements contained in this release to be covered by the safe harbor provisions of such Acts.

本新闻稿包括经修订的《1933年证券法》第27A节和经修订的《1934年证券交易法》第21E节所指的前瞻性声明。我们打算将本版本中包含的前瞻性声明纳入此类法案的安全港条款。

These forward-looking statements can sometimes be identified by the use of forward-looking words, such as “may,” “might,” “believe,” “will,” “expect,” “project,” “estimate,” “should,” “anticipate,” “plan,” “goal,” “continue,” “seek,” “intend,” “optimistic,” “aspire,” “confident” and other forms of these words and include, but are not limited to, statements made by Mr.

这些前瞻性陈述有时可以通过使用前瞻性词语来识别，例如“可能”、“可能”、“相信”、“将”、“期望”、“项目”、“估计”、“应该”、“预期”、“计划”、“目标”、“继续”、“寻求”、“打算”、“乐观”、“渴望”、“自信”和这些词语的其他形式，包括但不限于先生的陈述。

Zovighian and statements regarding expected product benefits, including safety and efficacy, other benefits including costs and health care resources, patient outcomes, objectives and expectations and other statements that are not historical facts. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict.

Zovighian和关于预期产品收益（包括安全性和有效性）的声明，其他收益（包括成本和医疗保健资源），患者结果，目标和期望以及其他非历史事实的声明。前瞻性陈述基于公司管理层做出的估计和假设，虽然它们本身不确定且难以预测，但被认为是合理的。

Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements..

我们的前瞻性声明仅在发布之日起生效，我们没有义务更新任何前瞻性声明以反映声明日期后的事件或情况。提醒投资者不要过度依赖此类前瞻性声明。。

Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission. These filings, along with important safety information about our products, may be found at Edwards.com..

前瞻性陈述涉及风险和不确定性，这些风险和不确定性可能导致结果与基于公司向证券交易委员会提交的文件中详述的许多因素的前瞻性陈述所明示或暗示的结果存在重大差异。这些文件以及有关我们产品的重要安全信息可以在爱德华兹网站上找到。。

Edwards, Edwards Lifesciences, the stylized E logo, CLASP, CLASP II, EARLY TAVR, PARTNER, PASCAL, TRISCEND, and TRISCEND II are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

Edwards、Edwards Lifesciences、程式化E徽标、CLASP、CLASP II、EARLY TAVR、PARTNER、PASCAL、TRISCEND和TRISCEND II是Edwards Lifesciences Corporation或其附属公司的商标。所有其他商标均为其各自所有者的财产。